MiNK Therapeutics Q4 2023 Earnings Report $9.09 +0.06 (+0.61%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast MiNK Therapeutics EPS ResultsActual EPS-$1.60Consensus EPS -$1.50Beat/MissMissed by -$0.10One Year Ago EPSN/AMiNK Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMiNK Therapeutics Announcement DetailsQuarterQ4 2023Date3/21/2024TimeN/AConference Call ResourcesINKT Earnings History Remove Ads MiNK Therapeutics Earnings HeadlinesHC Wainwright Cuts Earnings Estimates for MiNK TherapeuticsMarch 23, 2025 | americanbankingnews.comBrokers Issue Forecasts for INKT Q1 EarningsMarch 22, 2025 | americanbankingnews.com[OPEN NOW] New rules to trade options with.Here’s an update that could make your entire year. But first, a question. Could you get better wins if you applied a new set of rules to your trade? For example, when you meet your criteria to take a trade, could you improve your results by taking the same trade differently? From the audit I just did, it turns out the answer is a resounding YES! I applied a new set of rules to 100 live published trades from 2024. These 100 trades already got a whopping 69% win rate – taking a $10k model account risking 10% per trade to $63,304. But what happened when we applied these new rules? We got an 85.1% win rate and sent the same $10k account risking 10% per trade to over $200k!March 31, 2025 | WealthPress (Ad)What is William Blair's Estimate for INKT Q1 Earnings?March 21, 2025 | americanbankingnews.comEarnings call transcript: Mink Therapeutics Q4 2024 reports reduced net lossMarch 20, 2025 | uk.investing.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | msn.comSee More MiNK Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MiNK Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MiNK Therapeutics and other key companies, straight to your email. Email Address About MiNK TherapeuticsMiNK Therapeutics (NASDAQ:INKT), a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.View MiNK Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
